719 results found.
3Q14 Revenue: Medtronic
(for period ended 10/24/14) $746MM, +1% (U.S. $517MM, flat; ex-U.S. $229MM, +3%) Core Spine $551MM, flat Interventional Spine $75MM, -5% BMP $120MM, +9%   In the process of launching Prestige L...
3Q14 Revenue: Bacterin
$8.4MM, +7% OsteoSponge bone void filler represents ~60% of trailing revenue, OsteoSelect DBM putty ~17% In early 4Q, launched 3Demin (demineralized) line for procedures requiring larger volume of bone graft; Boat and Strip configurations targeted for complex...
BARE BONES® - October 21, 2014
Medtronic commenced U.S. launch of the DIVERGENCE™ Anterior Cervical Fusion system for the treatment of 1-level disc disease. DIVERGENCE supports simultaneous insertion of plate ...
BARE BONES® - October 20, 2014
Medtronic commenced launch of the Pure Titanium Coating platform of interbody fusion devices, including the CAPSTONE PTC™ and CLYDESDALE PTC globally, ANATOMIC PEEK PTC Cervical ...
BARE BONES® - October 13, 2014
Vexim will initiate a new clinical study to support its planned 2017 application for FDA 510(k) clearance to market SpineJack®. The prospective, multicenter, randomized study will compare Spi...
BARE BONES® - September 30, 2014
Preliminary 6-month results from a study comparing Vexim's SpineJack® to Medtronic's balloon kyphoplasty in the treatment of osteoporotic vertebral compression fractures revealed near...
BARE BONES® - September 17, 2014
Medtronic launched the KYPHON Express™ II Balloon Kyphoplasty Platform, including the next-generation KYPHON® Cement Delivery System (CDS). The KYPHON Express II features a maximum pressure rati...
BARE BONES® - September 16, 2014
Ortho Kinematics entered into an agreement granting Medtronic rights to promote the Vertebral Motion Analysis (VMA) test to spine surgeons. Studies indicate that VMA may produ...
BARE BONES® - August 28, 2014
Medtronic received FDA 510(k) clearance for the SHILLA™ Growth Guidance System for the treatment of pediatric patients with severe, progressive early-onset scoliosis. SHILLA features a
BARE BONES® - August 19, 2014
Medtronic posted FY1Q15 (ended 7/25/2014) spinal revenue of US $743MM, -3% from 1Q14. (Core Spinal $552MM, -2%, BMP $110MM, -11%) (
2Q14 Revenue: Bacterin
$8.9MM, +8% Estimates 2014 U.S. knee and ankle microfracture procedures of ~410,000; shows promise for distribution channel Claims 6.5% U.S. market share in DBM behind Medtronic, DePuy and Integra ~2/3 of revenue arises from spinal fusion ...
2Q14 Revenue: Symmetry Medical
$101.3MM, +2.3% Instruments $29.8MM, +6% Implants $29.4MM, +5% Cases $17.3MM, +1% Other $4.4MM, +29% Surgical $20.4MM, -9%   Announced proposed sale of OEM Solutions business...
BARE BONES® - July 28, 2014
Medtronic received FDA approval to market the PRESTIGE® LP artificial disc to treat single-level cervical disc disease. Further, the company acquired Visualase, developer of an MRI-gu...
BARE BONES® - June 15, 2014
Medtronic (MDT) entered into a definitive agreement to acquire Covidien (COV) in a cash-and-stock transaction valued at ~US $42.9BB. Upon completion, which is expected in early 2015
BARE BONES® - June 4, 2014
Medtronic is reportedly in early stages of evaluating a bid for Smith & Nephew. (Reuters,
BARE BONES® - June 3, 2014
Humana filed a suit against Medtronic, alleging that fraudulent misrepresentation caused Humana to pay for "ineffective and unsafe use" of Infuse. (
BARE BONES® - May 20, 2014
Medtronic posted fiscal year 2014 (ended 4/25/14) spinal revenue of US $3,041MM, -2% from 2013. (Core Spine $2,570MM, flat; BMP $471MM, -11%) (Growth reflects constant currency.) (
1Q14 Revenue: Medtronic
(fiscal year 2014 ended 4/25/14) $3,041MM, -2% (U.S. $2,103MM, -4%; ex-U.S. $938MM, +4%) Core Spine $2,570MM, flat (U.S. $1,694MM, -2%; ex-U.S. $876MM, +4%) BMP $471MM, -11% (U.S. $409MM, -13%; ex-U.S. $62MM, +5%)  
BARE BONES® - May 6, 2014
Medtronic (MDT) has agreed with certain Plaintiffs' counsel to settle their inventories of filed and unfiled product liability claims related to INFUSE® Bone Graft. Terms indicate that MDT has agreed, subject...
BARE BONES® - April 30, 2014
Medtronic (MDT) denied allegations that it owes US $15MM to Pabban Development from a transaction to acquire its spinal cement device, and claimed that Pabban owes $33MM to MDT for fra...
4Q13/2013 Revenue: Bacterin
4Q13 tissue revenue: $8.3MM, +2% 2013 tissue revenue: $33.1MM, flat Business model going forward: direct sales to orthopaedics and neurosurgery via hybrid model; exploring private label relationships Increased productivity: 25 sal...
BARE BONES® - February 18, 2014
Medtronic reported 3Q14 (ended 1/24/14) spinal revenue of US $744MM, flat vs. 3Q13. (Core Spinal $631MM, flat; Biologics $113MM, -1%) (
4Q13/2013 Revenue: Medtronic
Fiscal 3Q14 ended 1/24/14: $744MM, flat (U.S. $517MM, -1%; ex-U.S. $227MM, +2%) Core Spinal $631MM, flat (U.S. $419MM, -0.7%; ex-U.S. $212MM, +2%) Biologics $113MM, -1% (U.S. $98MM, -2%; ex-U.S. $15MM, +7%)   E...
2013: Who, What, Where and When in an Orthopaedic Year
Before we dive into 2014, let’s review what 2013 wrought. We’ve collected the start-ups, expansions and closures, mergers and acquisitions, fundings, first 510(k)s and products launched across the orthopaedic universe in the preceding 12 months. (Please note, start-ups, first 510(k...
BARE BONES® - December 6, 2013
Seven-year clinical and radiographic outcomes of artificial disc replacement with Medtronic's PRESTIGE® Cervical Disc vs. anterior cervical discectomy and fusion revealed 72.6% overall patient success...
  • 8401 Chagrin Road, Suite 18
  • Chagrin Falls, Ohio 44023 USA
  • Phone: 440.543.2101 • Fax: 440.543.2122
  • ©1992-2019 ORTHOWORLD
  • All Rights Reserved.
  • Site Managed By:
  • Open Professional Group